Media Contact: Sandra VanE-mail: [email protected]Tel. 1-800-396-1002Please do not publish this e-mail address or telephonenumber in your story. They are for media use only.
==
LOS ANGELES (June 13, 2001) -- Cedars-Sinai Medical Center's Stanley C. Jordan, M.D., was recognized for more than two decades of research when the American Society of Transplantation presented him with its Novartis Established Investigator Clinical Science Award on May 14. A reception in his honor will be held at the medical center later this month.
The award presentation was part of AST's professional session, called "Transplant 2001," held May 11 through 16 in Chicago.
Dr. Jordan, medical director of Cedars-Sinai's Kidney Transplant Program, director of Pediatric Nephrology and Transplant Immunology, and professor of pediatrics at the University of California, Los Angeles, has directed research leading to major advances in diagnostic and treatment approaches in the care of patients receiving transplanted organs.
He developed a process that uses intravenous immunoglobulin (IVIG) to reduce the risk of rejection in difficult cases in which other medications have failed. He also created a technique to detect post-transplant lymphoproliferative disorder (PTLD) in its earliest stages when intervention is most effective. PTLD is a form of cancer that can have catastrophic effects on children who receive donated organs.
The AST's Established Investigator honor includes a $25,000 award to further the institution's research, and is presented to candidates who are at least 45 years of age, at the mid-point of their careers in the field of transplantation, have made significant contributions, and are recognized as experts in their field.
After receiving his undergraduate and medical degrees from the University of North Carolina, Chapel Hill, Dr. Jordan completed a pediatric internship and residency at UCLA. He completed fellowships in pediatric nephrology, experimental pathology, and dialysis and transplantation, and he is board certified in pediatrics, pediatric nephrology, and diagnostic laboratory immunology.
With his extensive knowledge of immunology and transplantation, Dr. Jordan has served on the editorial boards of numerous professional journals, and he has been invited to serve on a variety of prestigious committees. In the past several years, for example, he participated in two task forces assembled by the National Institutes of Health's National Institute of Allergy and Infectious Diseases, one of which was commissioned to develop research priorities for kidney transplantation for the 21st century.
"It is a tremendous honor to be recognized by the American Society of Transplantation," said Dr. Jordan. "Like my research colleagues, I'm fortunate to be able to contribute to the progress being made in transplantation, and in pediatric transplantation in particular. To have a group of our peers in the scientific community take note of our efforts is the highest compliment."
Dr. Jordan said he and his team members were also honored to discover that seven of their scientific abstracts had been accepted for presentation at Transplant 2001. This is especially gratifying because the AST meeting was held jointly with the American Society of Transplant Surgeons (ASTS), putting presentation time at a premium.
According to the AST and ASTS, Transplant 2001 was "designed for physicians, surgeons, scientists, nurses, organ procurement personnel, and pharmacists who are interested in the clinical and research aspects of solid organ and tissue transplantation." Abstracts accepted for presentation will also be published in a supplement to the new joint ASTS/AST journal, American Journal of Transplantation.
# # #
For media information and interviews, please contact Sandra Van via e-mail at [email protected] or by calling 1-800-396-1002. Please do not publish this contact information in your stories. It is for media use only. Thank you.
RSS